Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis - Wikidata - awgldk - TriplyDB

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

http://www.wikidata.org/entity/Q37599251

about

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi.CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence The evolving role of biosimilars in haematology-oncology: a practical perspective.Biosimilar medicines - Review.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs.Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.Improving Access to Cancer Treatments: The Role of Biosimilars.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group

P2860

Q28078423-546F3C5A-BFF8-4069-8824-66972574D23B Q35916171-8D61AB34-BA69-420C-8860-0D35539703F6 Q35942794-C6CADC51-D6A4-4B52-A892-4CA60F94816A Q36247037-D176CE04-768C-4759-BE44-71219C84B5CF Q36291259-45276739-E5FD-449D-8C00-4FDE4E4EF354 Q38833786-AF818DAA-B9B4-47F2-85D5-1A56AEE132EF Q38896113-54F4CB90-A74E-41E9-9ECE-EA5BB087F4E5 Q39662554-2B2E376D-DF7E-4434-B8FC-3AEC756DBD47 Q39665991-8FC1FEDA-7E1E-48C9-9211-7D06C4B35457 Q47099597-9D63CB41-84F4-47D7-B24C-064A7512E9E9 Q49979586-9EB55BF8-7AFD-46EE-B824-5565DB04EAD6 Q51034561-B9117510-0A94-40DD-8F2B-00340E0E7190 Q55283747-BEFAAADD-3308-4052-87B6-4CB17C2668A3 Q58801965-6CE05142-EF95-4B23-BECB-5D9CD747C5FD

P2860

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

http://www.wikidata.org/entity/Q37599251

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comparison of the efficacy and ...... rapy: A retrospective analysis

@en

Comparison of the efficacy and safety of Rituximab

@nl

type

label

Comparison of the efficacy and ...... rapy: A retrospective analysis

@en

Comparison of the efficacy and safety of Rituximab

@nl

prefLabel

Comparison of the efficacy and ...... rapy: A retrospective analysis

@en

Comparison of the efficacy and safety of Rituximab

@nl

P1433

Q37599251-3CA2C3E4-7412-4381-A868-29534562FB6A

P1476

Q37599251-69E46B3E-F69B-4122-967D-4092D651D268

P2093

Q37599251-07769386-D600-4F1A-AF2E-AB2F1EA47FD3

Q37599251-0F64FDF1-99E5-4783-B2AA-D3BA5E000C5A

Q37599251-181ACC7E-646A-410E-A15A-AEB8137F09C0

Q37599251-187290D3-5E79-414E-9A9B-CEF9F96A93B8

Q37599251-2E66DC21-9B2D-47DA-9EB5-791EDB4E8EA8

Q37599251-37033F0D-A419-4486-A242-B0DFFE4590CF

Q37599251-7EB417E9-C232-4E14-8097-48B8652695F7

Q37599251-805C297A-48B5-49A0-BE30-602525DD83BD

Q37599251-818F04C2-CFD2-4A66-8D4D-565BA86D99CB

Q37599251-D20A643E-7904-4A62-8AA4-8D7D92B02876

P2860

Q37599251-11524A52-E3EF-4EC1-B0CB-DD0D98F2260D

Q37599251-2514C5CF-A60B-4A00-ABE3-2876081348B6

Q37599251-27F3D420-D4EC-4D9F-8DD3-964651A60D7B

Q37599251-28033F00-CDE8-422D-8282-B91B08071899

Q37599251-3F142CBC-16D8-457E-81B7-9F12BBCB8833

Q37599251-3FCAD587-42BB-4973-B9AC-CB009C628C02

Q37599251-5B3C5484-916F-4427-979D-DF7267A5E98F

Q37599251-6CC2816C-D54D-482F-A904-028560F55C32

Q37599251-6FA04203-8E70-42CF-8274-2A036084FD78

Q37599251-7AF8F99D-F180-4D31-A31D-77114EDB9594

P304

Q37599251-6C7FB77D-201D-4473-B797-458FC064E122

P31

Q37599251-74FF50F3-1B36-4273-BE48-54DA06D31D8E

P356

Q37599251-77D9E724-B57A-4FB2-88F8-13AC4EEAA58A

P433

Q37599251-1603F24E-DF66-4EF7-BE81-4F715E220965

P478

Q37599251-C335CC35-FA96-40A4-B5F9-986836E9B06A

P577

Q37599251-67F6650A-6BFD-46CE-A545-5957A865BA47

P5875

Q37599251-E23CC8F4-F370-4C4D-9E17-54FA82FA194F

P698

Q37599251-783F7153-4182-41E1-B693-5DAB5CEBD221

P921

Q37599251-E951243A-5D56-47BE-A704-F8A5BD281D1F

P932

Q37599251-1D6AAD4C-A84D-455D-A4D8-00AF00526178

P356

0971-5851.125248

P1433

Indian Journal of Medical and Paediatric Oncology

P1476

Comparison of the efficacy and ...... rapy: A retrospective analysis

@en

P2093

Bhausaheb Bagal

http://www.w3.org/2001/XMLSchema#string

Hari Menon

http://www.w3.org/2001/XMLSchema#string

Jayanta Gawande

http://www.w3.org/2001/XMLSchema#string

Manju Sengar

http://www.w3.org/2001/XMLSchema#string

Navin Khattry

http://www.w3.org/2001/XMLSchema#string

Partha Sarathi Roy

http://www.w3.org/2001/XMLSchema#string

Preeti Pawaskar

http://www.w3.org/2001/XMLSchema#string

Reena Nair

http://www.w3.org/2001/XMLSchema#string

Sadashiv Karankal

http://www.w3.org/2001/XMLSchema#string

Sadhana Kannan

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Biosimilar medicines and cost-effectiveness.

The regulatory framework of biosimilars in the European Union.

Biosimilars: what clinicians should know.

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Non-Hodgkin's lymphoma: is India ready to incorporate recent advances in day to day practice?

Heterogeneity of recombinant antibodies: linking structure to function.

Revised response criteria for malignant lymphoma.

P304

292-298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0971-5851.125248

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260611310

http://www.w3.org/2001/XMLSchema#string

P698

24604960

http://www.w3.org/2001/XMLSchema#string

P921

P932

3932598

http://www.w3.org/2001/XMLSchema#string